# Monopar Therapeutics Inc. (MNPR): MoatMap facts

As of 27 Oct 2026. Research data, not investment advice.

As of 27 Oct 2026, MoatMap's StockRank for Monopar Therapeutics Inc. (MNPR) is 34/100, ranked against 24,000+ stocks in 35 markets (Quality 40, Value 27, Momentum 56, each scored against its sector).

- StockRank: 34/100, a percentile across 24,000+ stocks in 35 markets (100 is best).
- Quality 40, Value 27, Momentum 56: each a 0-100 percentile within Healthcare.
- Position: #17,363 overall, #1,508 in Healthcare.
- Listing: United States, NCM; Healthcare / Biotechnology.
- Last close: 70.54 USD on 26 Oct 2026.
- Insider filings, last 180 days: directors sold USD 4.1M.

Source: https://moatmap.ai/stock/MNPR
How the scores work: https://moatmap.ai/methodology
Does StockRank work? The public record: https://moatmap.ai/decile-tracker